Product
QL0911
4 clinical trials
3 indications
Indication
Chemotherapy-induced ThrombocytopeniaIndication
Immune ThrombocytopeniaClinical trial
Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III TrialStatus: Completed, Estimated PCD: 2021-12-13
Clinical trial
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase 3 Study Evaluating the Efficacy and Safety of Recombinant Human Thrombopoietin Mimetic Peptide-Fc Fusion Protein for Injection (QL0911) in Chemotherapy- Induced ThrombocytopeniaStatus: Completed, Estimated PCD: 2021-09-10
Clinical trial
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase 3 Study Evaluating the Efficacy and Safety of Recombinant Human Thrombopoietin Mimetic Peptide-Fc Fusion Protein for Injection (QL0911) in the Prevention of Chemotherapy- Induced ThrombocytopeniaStatus: Recruiting, Estimated PCD: 2023-05-01
Clinical trial
Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia.Status: Not yet recruiting, Estimated PCD: 2026-07-01